NASDAQ:BIS ProShares UltraShort Nasdaq Biotechnology (BIS) Price, Holdings, & News $10.93 +0.11 (+1.02%) Closing price 08/24/2026 03:59 PM EasternExtended Trading$10.94 +0.01 (+0.05%) As of 08/24/2026 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsNews and TrendsOptions ChainOwnershipSEC Filings About ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BIS alerts:Sign Up Key Stats Today's Range$10.90▼$11.0350-Day Range$10.53▼$16.7052-Week Range$10.51▼$29.18Volume4,029 shsAverage Volume8,132 shsMarket Capitalization$1.86 millionAssets Under ManagementN/ADividend Yield7.14%Net Expense Ratio0.95%Aggregate RatingN/A ETF Overview ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in equity securities and derivatives that have similar daily performance characteristics as twice (200%) the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund. Read More ProShares UltraShort Nasdaq Biotechnology ExpensesTypeBISHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.55%0.57%0.54%0.53%Other Expenses2.45%0.52%0.53%0.39%0.54%Total Expense3.20%0.76%0.75%0.69%0.73%Fee Waiver-2.25%-0.85%-0.67%-0.41%-0.68%Net Expense0.95%0.58%0.63%0.61%0.60% Receive BIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares UltraShort Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIS ETF News HeadlinesShort Interest in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Rises By 58.6%August 18, 2026 | americanbankingnews.comBIS says AI boom risks clouding central banks' inflation signalsJuly 28, 2026 | reuters.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)ProShares Ultra Nasdaq Biotechnology Dividends | NASDAQ:BIB | BenzingaJuly 8, 2026 | benzinga.comBIS dares to blaspheme as AI bubble fears waneJune 30, 2026 | reuters.comBIS says debt, AI boom and fragilities raise global risksJune 28, 2026 | reuters.comSee More Headlines BIS ETF - Frequently Asked Questions How have BIS shares performed this year? ProShares UltraShort Nasdaq Biotechnology's stock was trading at $18.96 at the beginning of the year. Since then, BIS shares have decreased by 42.4% and is now trading at $10.93. When did ProShares UltraShort Nasdaq Biotechnology's stock split? ProShares UltraShort Nasdaq Biotechnology's stock reverse split on the morning of Tuesday, August 18th 2020.The 1-4 reverse split was announced on Tuesday, August 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 17th 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of ProShares UltraShort Nasdaq Biotechnology? Shares of BIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProShares UltraShort Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares UltraShort Nasdaq Biotechnology investors own include Micron Technology (MU), Inovio Pharmaceuticals (INO), Sanofi (SNY), Intel (INTC), Meta Platforms (META), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Fund Details IssuerProShares Fund NameProShares UltraShort Nasdaq Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:BIS Inception Date4/7/2010 Fund ManagerMichael Neches, Tarak Dave Webwww.proshares.com Phone+1-240-4976400Fund Focus Asset ClassEquity BenchmarkNasdaq Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings28 Fund Statistics Assets Under Management$0.00 Average Daily Volume$8.61 thousand Discount/Premium0.00% Leveraged-2.00 Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors, LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJ.P. Morgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest7,300 shs Miscellaneous Outstanding Shares170,000Beta-1.18 Creation Unit50,000 Creation Fee$250.00 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report Top 6 BIS HoldingsNET OTHER ASSETS (LIABILITIES)Holding Weight: 0.00%NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NAHolding Weight: -30.24%NASDAQ BIO INDEX SWAP BNP PARIBASHolding Weight: -36.41%NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NAHolding Weight: -37.06%NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALEHolding Weight: -46.17%NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AGHolding Weight: -51.04%Full Holdings Details This page (NASDAQ:BIS) was last updated on 8/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares UltraShort Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares UltraShort Nasdaq Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
